~~<i id='203A4EE67C'><strike id='203A4EE67C'><tt id='203A4EE67C'><pre id='203A4EE67C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：knowledge 2025-09-30 00:38:04 - browse：4

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Stem cell treatment guidelines are released by FDA

leisure time

explore

hotspot

explore

leisure time

BillSikes/APVertexPharmaceuticalshasspentdecadestryingtodevelopmoleculesthatreducepainsafelyandpoten

WSS

Humana sues Biden admin over Medicare Advantage audit rule

The (many) problems with a new study criticizing cancer screening

What American doctors can learn from their Israeli counterparts

Medicaid rebukes states for mistakenly disenrolling children

No plane should take off without an EpiPen onboard

No plane should take off without an EpiPen onboard

explore

hotspot

leisure time

Peter Hotez and the public health issue of online harassment

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

23andMe had bad news about my health. I wish a person had delivered it

Trump indictment: Who are the 'co

Cancer drug shortages should be causing more outrage

Ethical issues complicate the benefits of medical crowdfunding

Medical leaders decry Supreme Court decision on affirmative action

‘Oppenheimer’ and the risks of AI in health care

Activists slam private health insurers over coverage restrictions

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

leisure time

The 10 drugs up first for Medicare price negotiation

Trump indictment: Who are the 'co

Weighted lottery helped low

What drug price negotiations mean for Medicare Part D

What to expect as Trump is arraigned on his Jan 6. indictment

Infectious disease expert Jeanne Marrazzo assumes Fauci role

explore

hotspot

explore

leisure time